EHA Update 2017 New Data on the Benefits of Novartis Ruxolitinib (Jakavi®) in Polycythemia vera and Myelofibrosis

被引：0
|
作者：
不详
机构：
来源：
TRANSFUSION MEDICINE AND HEMOTHERAPY | 2017年 / 44卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：372 / 372
页数：1
相关论文
共 50 条
  • [41] An Individual Patient Supply Program for Ruxolitinib for the Treatment of Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF)
    Barosi, Giovanni
    Agarwal, Mohan
    Zweegman, Sonja
    Willenbacher, Wolfgang
    Pakstyte, Sima
    Raymakers, Reinier
    Cantoni, Nathan
    Modi, Ankur
    Khan, Mahmudul
    Perez, Jose Ricardo
    Hasselbalch, Hans
    Vargas Viveros, Jose Pablo
    Linardi, Camila C. G.
    Gisslinger, Heinz
    Daumas Gabriel, Adelmo Henrique
    Palandri, Francesca
    Lavie, David
    Harrison, Claire N.
    BLOOD, 2012, 120 (21)
  • [42] The Use of Erythropoietic-Stimulating Agents (ESAs) with Ruxolitinib in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), and Post-Essential Thrombocythemia Myelofibrosis (PET-MF)
    McMullin, Mary Frances
    Harrison, Claire N.
    Niederwieser, Dietger
    Demuynck, Hilde
    Jakel, Nadja
    Sirulnik, Andres
    McQuity, Mari
    Stalbovskaya, Viktoriya
    Recher, Christian
    Theunissen, Koen
    Gisslinger, Heinz
    Kiladjian, Jean-Jacques
    Al-Ali, Haifa-Kathrin
    BLOOD, 2012, 120 (21)
  • [43] Cause-specific mortality following polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the US population, 2001-2017
    Dores, Graca M.
    Curtis, Rochelle E.
    Linet, Martha S.
    Morton, Lindsay M.
    AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (12) : E451 - E454
  • [44] Outcomes of Fedratinib in Routine Treatment of Ruxolitinib-Resistant or -Refractory Patients with Primary and Post-Polycythemia Vera or Essential Thrombocythemia Myelofibrosis: A Nationwide Retrospective Study
    Duek, Adrian
    Tzinman, Alexandra
    Maziuk, Kira
    Levy, Assaf
    Ellis, Martin
    Stemer, Galia
    Abulafia, Adi Shacham
    Cohen, Amos
    Lavi, Noa
    Ronson, Aaron
    Braester, Andrey
    Shapira, Shirley
    Canaani, Jonathan
    Volchek, Yulia
    Leiba, Ronit
    Leiba, Merab
    ACTA HAEMATOLOGICA, 2024,
  • [45] Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study
    Palandri, Francesca
    Palumbo, Giuseppe A.
    Iurlo, Alessandra
    Polverelli, Nicola
    Benevolo, Giulia
    Breccia, Massimo
    Abruzzese, Elisabetta
    Tiribelli, Mario
    Bonifacio, Massimiliano
    Tieghi, Alessia
    Isidori, Alessandro
    Martino, Bruno
    Sgherza, Nicola
    D'Adda, Mariella
    Bergamaschi, Micaela
    Crugnola, Monica
    Cavazzini, Francesco
    Bosi, Costanza
    Binotto, Gianni
    Auteri, Giuseppe
    Latagliata, Roberto
    Ibatici, Adalberto
    Scaffidi, Luigi
    Penna, Domenico
    Cattaneo, Daniele
    Soci, Francesco
    Trawinska, Malgorzata
    Russo, Domenico
    Cuneo, Antonio
    Semenzato, Giampietro
    Di Raimondo, Francesco
    Aversa, Franco
    Lemoli, Roberto M.
    Heidel, Florian
    Reggiani, Maria L. B.
    Bartoletti, Daniela
    Cavo, Michele
    Catani, Lucia
    Vianelli, Nicola
    SEMINARS IN HEMATOLOGY, 2018, 55 (04) : 248 - 255
  • [46] Long-Term Survival Data in 652 Patients with Primary Myelofibrosis or Polycythemia Vera-Trends in Recent Years
    Vaidya, Rakhee
    Gangat, Naseema
    Siragusa, Sergio
    Schwager, Susan
    Hanson, Curtis A.
    Elliott, Michelle
    Pardanani, Animesh D.
    Tefferi, Ayalew
    BLOOD, 2009, 114 (22) : 1137 - 1137
  • [47] Interim Analysis of a Phase II Pilot Trial of Ruxolitinib Combined with Danazol for Patients with Primary Myelofibrosis (MF), Post Essential Thrombocythemia-Myelofibrosis (Post ET), and Post Polycythemia Vera Myelofibrosis (PV MF) Suffering from Anemia
    Gowin, Krisstina L.
    Dueck, Amylou C.
    Mascarenhas, John O.
    Hoffman, Ronald
    Reeder, Craig B.
    Camoriano, John
    Gano, Katherine
    Ghurye, Vineta
    Reddy, Sravan Nagi
    Koenig, Patricia
    Fauble, Veena
    Tibes, Raoul
    Mesa, Ruben
    BLOOD, 2014, 124 (21)
  • [48] Population Pharmacokinetic Analysis of Orally-Administered Ruxolitinib (INCB018424 Phosphate) in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia Myelofibrosis (PET MF)
    Chen, Xuejun
    Williams, William V.
    Sandor, Victor
    Yeleswaram, Swamy
    JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 53 (07): : 721 - 730
  • [49] Interim Analysis of Registry of Ruxolitinib Treatment in Patients with Intermediate-2 or High Risk Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) in Taiwan
    Hou, Hsin-An
    Lin, Chien-Chin
    Kuo, Ming-Chung
    Lin, Shyuann-Yuh
    Gau, Jyh-Pyng
    Wang, Ming-Chung
    Chang, Ming-Chih
    Chen, Tsung-Chih
    Yeh, Su-Peng
    Chen, Yeu-Chin
    Huang, Cih-En
    Chen, Chieh-Wen
    Lee, Yee-Ming
    Ku, Fan-Chen
    Shih, Lee-Yung
    BLOOD, 2019, 134
  • [50] Phenotypic variations and new mutations in JAK2 V617F-neagative polycythemia vera, erythrocytosis, and idiopathic myelofibrosis
    Williams, Donna M.
    Kim, Ann H.
    Rogers, Ophelia
    Spivak, Jerry L.
    Molitemo, Alison R.
    EXPERIMENTAL HEMATOLOGY, 2007, 35 (11) : 1641 - 1646
12345